48.00 -0.03 (-0.06%)
Pre-Market: 8:31AM EDT
|Bid||46.50 x 800|
|Ask||48.20 x 900|
|Day's Range||46.75 - 50.86|
|52 Week Range||20.10 - 300.00|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||94.86|
Tilray Inc. (TLRY), a global pioneer in cannabis research, cultivation, production and distribution, today announced it has imported medical cannabis oral solutions in bulk into the United Kingdom from its Good Manufacturing Practices (GMP)-certified facility in Canada. This export allows Tilray to provide authorized U.K. patients in need with a locally maintained supply of medical cannabis oral solutions. In September 2018, Tilray announced the successful import of Tilray 2:100 medical cannabis oil for a pediatric patient in need in the United Kingdom.
(Bloomberg) -- Tilray Inc. has imported its first bulk supply of medical cannabis oil into the U.K., after controversy over the confiscation of one of the Canadian company’s products led to an easing of restrictions.The oral solution, containing both the psychoactive THC and non-intoxicating CBD compounds, is used to treat pain, chemotherapy-induced nausea and vomiting and multiple sclerosis-associated spasticity. It has already been supplied in bulk to Germany, Croatia, Cyprus and Malta.Another cannabis-based Tilray product that helps treat epilepsy was confiscated last year from a Northern Irish child, Billy Caldwell, sparking a media campaign to permit the substance for medical use. The U.K. government in November made it legal for specialist doctors to prescribe medical marijuana for patients with severe clinical need.“This allows us to hold a reliable supply in the U.K. so we can avoid having to import on a per-patient basis, shortening the amount of time from prescription to the patient getting the product,” Catherine Jacobson, Tilray’s vice president of medical and regulatory affairs, said in an interview.“If access is too difficult patients will just go to the black market,” she said. “We’ve seen that happen and it’s really dangerous for patients.”The Nanaimo, British Columbia-based cannabis company is also hoping to import bulk supplies of its five other medical cannabis products into the U.K. by the end of the year.Medical UseTilray, which has joined forces with Budweiser brewer Anheuser-Busch InBev NV to research cannabis-infused beverages, is focused on health uses in its European operations for now, Jacobson said.“Any company has to look at all the markets available to them but we are steadfastly focused on the medical market,” Jacobson said.The company has also signed a partnership with Swiss drug giant Novartis AG to develop and distribute medical marijuana in legal jurisdictions around the world. The Canadian company is in talks with research groups in the U.K. to launch clinical trials in the country, she said.To contact the reporter on this story: Ellen Milligan in London at firstname.lastname@example.orgTo contact the editors responsible for this story: Eric Pfanner at email@example.com, John LauermanFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
In the week ending June 21, Tilray (TLRY) was among the biggest gainers in the cannabis sector. Tilray stock gained as much as 29.3% from the closing in the week ending June 14.
Blueberries Medical Corp. (CSE: BBM) (BBRRF) (1OA.F) ("Blueberries" or the "Company"), a leading Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce the appointment of Ian D. Atacan CPA, CMA, MBA, B.Sc. Mr. Reid will work with Mr. Atacan and the Company to support a seamless transition, and the Company would like to thank Mr. Reid for his services.
CBD-rich hemp could be a high-growth stepping stone into the U.S. for these half-dozen Canadian cannabis stocks.
Which stock is likely to be the bigger winner between a top Canadian cannabis producer and one of the largest multistate U.S. cannabis companies?
Canopy Growth shares plunged after reporting a larger per-share loss during its fiscal fourth quarter, and warned its merger would hit future profit.
Canopy Growth (WEED) was trading at a forward multiple of 10x, which was at a premium to the median level. However, the stock was trading at a discount to its historical level of 15x.
Cannabis sector stocks haven't risen in the past three months due to disappointing earnings, which largely missed the expectations. Investors hoped that the companies would post huge sales figures.
CGC analysts are estimating an EPS of -0.17 and revenues of $71 million. Shareholders are voting today on whether to acquire Acreage Holdings, which could propel CGC one way or the other.
Shoppers Drug Mart is partnering with TruTrace Technologies Inc. to bolster its medical cannabis retail platform.
NEWTOWN SQUARE, PA / ACCESSWIRE / June 17, 2019 / Kaskela Law LLC is investigating Tilray, Inc. (NASDAQ: TLRY) ("Tilray" or the "Company") on behalf of the Company's shareholders. Since ...
Tilray Inc. (NASDAQ:TLRY) and Aphria Inc (TSX:APHA)(NYSE:APHA) are two marijuana stocks that you shouldn't buy unless you have a higher risk appetite.
After a solid few years, marijuana stocks like Aphria Inc (TSX:APHA)(NYSE:APHA) could collapse in the second half of 2019.
Tilray, Inc. (TLRY), a global pioneer in cannabis production, research, cultivation and distribution, today announced the expansion of its global senior leadership team with the appointment of Kristina Adamski as Executive Vice President, Corporate Affairs. In her new role, Kristina will lead Tilray’s corporate affairs team, developing the team globally and overseeing the company’s public relations, corporate social responsibility and government affairs functions.
Massive growth is coming for the global cannabis market, according to Tilray's top execs. And they think Tilray is poised to be a big winner.
CALGARY, June 13, 2019 /CNW/ - Inner Spirit Holdings Ltd. ("Inner Spirit" or the "Company") (CSE:ISH.CN - News), a Canadian company establishing a national network of adult-use cannabis stores under its Spiritleaf brand, is pleased to announce that it completed the second tranche of its previously announced cross-investment with Tilray, Inc. ("Tilray") (NASDAQ:TLRY - News) and its wholly owned subsidiary High Park Holdings Ltd. ("High Park"). Pursuant to the terms of the investment agreement entered into in December 2018, as amended, Tilray Inc. and Inner Spirit have exchanged shares valued at $1.5 million. "High Park has been a great strategic partner and partnerships like this enable our Company to grow the Spiritleaf retail brand and create value for investors in Canada's adult-use cannabis market.
The Canadian stocks trade at more than 10 times the companies’ 2020 sales, on average, while stocks of the U.S. firms go for about three times, Compass Point points out.
Tilray's Target Price: Consensus Trends Lower in JuneTilrayOn June 10, Tilray (TLRY) rose 12.1%. The company issued a press release related to a lockout period extension for one of its biggest shareholders. The shareholder accounts for nearly 77%